Skip to main content

Table 9 Association between sponsor and clinical outcomes: stool characteristics

From: Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: A Systematic Review

Stool characteristics

Source of funding

Positive*

Negative*

Neutral*

Chi-square p value

Fisher’s exact p value

n (%)$$

n (%)$$

n (%)$$

Stool Frequency N = 37

Industry

7 (18.9)

 

22 (59.5)

0.501

0.540

None/Not clear

3 (8.1)

 

4 (10.8)

  

Non industry

  

1 (2.7)

  

Stool Consistency n =37

Industry

14 (37.8)

 

15 (40.5)

0.562

1.00

None/Not clear

4 (10.8)

 

3 (8.1)

  

Non industry

  

1 (2.7)

  

Stool pH N =13

Industry

7 (53.8)

 

2 (15.4)

0.305

1.00

None/Not clear

4 (30.8)

    

Non industry

     

Stool Short Chain Fatty Acids N = 9

Industry

2 (22.2)

 

4 (44.4)

0.687

1.00

None / Not clear

1 (11.1)

 

1 (11.1)

  

Non industry

  

1 (11.1)

  

Flatulence / Gas N = 16

Industry

  

15 (93.8)

Not valid

 

None/Not clear

  

1 (6.3)

  

Non industry

  

0

  

Diarrhoea, Diarrhoea episodes N = 19

Industry

3 (15.8)

1 (5.3)

10 (52.6)

0.771

1.00

None/Not clear

  

2 (10.5)

  

Non industry

  

3 (15.8)

  

Constipation N = 3

Industry

1 (33.3)

 

1 (33.3)

0.386

1.00

None/Not clear

  

1 (33.3)

  
 

Non industry

  

0

  
  1. $$Overall percentage.
  2. *Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in favour of experimental group).
  3. *Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups.
  4. *Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05.